Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?

Kate Smith-Jackson, Kevin J. Marchbank


The need for better anti-complement drugs in certain complement mediated diseases and disease states remains pressing (1). The recent data published by Ueda et al. (2), appears to offer another highly effective solution to target complement activation in atypical haemolytic uraemic syndrome (aHUS).